A swallowed peptide cut one kind of cholesterol 57.1 percent in a trial

A peptide is a short chain of amino acids, and the reason peptide medicines are injected is that the gut is built to pull chains like that apart. Enlicitide is a peptide that is swallowed. Its chain is joined end to end into a ring, and the ring, along with a long list of chemical changes along it, is what lets enough of the molecule survive to be absorbed. In 2026 it became an approved tablet for lowering cholesterol, which makes it a useful place to look at what engineering a peptide into a pill settles and what it leaves open [1][3].

What the molecule blocks

Its target is PCSK9, a protein circulating in blood that shortens the working life of the receptors the liver uses to pull low density lipoprotein cholesterol out of circulation. Less of that protein at work means those receptors last longer and more cholesterol is cleared. Injected antibodies have been blocking it for years. Blocking it with something swallowed is the new part [1].

The trial

CORALreef Lipids was a multinational trial in which neither participants nor investigators knew who was receiving what. It enrolled adults who had already had a major cardiovascular event and whose low density lipoprotein cholesterol was 55 milligrams per decilitre or higher, and adults at risk of a first event whose level was 70 or higher. Of the 2,909 participants in the main analysis, 1,935 received the tablet and 969 received an inactive tablet, daily for 52 weeks. Average age was 63 years, 39.3 percent were women, and average low density lipoprotein cholesterol at the start was 96.1 milligrams per decilitre [1].

The main measurement was the percent change in that cholesterol at week 24. It fell by an average of 57.1 percent in the treated group, with a range of statistical uncertainty from 61.8 to 52.5 percent, and rose by 3.0 percent in the comparison group. The difference between the groups was 55.8 percentage points, with a range from 60.9 to 50.7, at a P value below 0.001. Non HDL cholesterol, apolipoprotein B and lipoprotein(a) also fell further than in the comparison group. The report states that the rate of side effects did not appear to differ [1].

The part that is new chemistry

A separate 2026 paper in Science is about how the molecule is made rather than what it does, and it is where the genuinely new science sits. Assembling a heavily modified ring shaped peptide at scale has historically taken a long chain of steps, many of them spent putting temporary chemical shields on parts of the molecule and taking them off again. The team reported building it with engineered enzymes that join the fragments and close the ring without those shields, and with crystallisations that remove a purification stage. They report cutting the number of steps by more than half against the previous best method [2].

Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs.

Klapars and colleagues, Science, 2026 [2]

That sentence is the reason the manufacturing paper matters beyond this one molecule. If rings of this kind can be made in half the steps and without shields, the argument that a peptide has to be an injection weakens for reasons that are industrial as much as biological [2].

What the label reveals about the gut

The approved United States labelling shows how partial the win over digestion is. The tablet is to be taken on an empty stomach in the morning with water, black coffee or plain tea, swallowed whole, and at least 30 minutes have to pass before any food or other drink. Those instructions exist because the molecule is still in a race with digestion. The ring wins it enough time, not unlimited time [3].

The indication section is careful in a way worth reading closely, because it separates what this medicine has shown from what other medicines have shown [3].

Cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors as an add-on to statin therapy.

United States prescribing information for enlicitide, Indications and Usage [3]

The sentence points at trials of other medicines. It says that lowering this kind of cholesterol has been shown to reduce major cardiovascular events when the lowering was done with statins or with the injected antibodies. It does not say that this tablet has been shown to do it [3].

What it does not show

That is the open question. A 57.1 percent reduction in a laboratory value is a marker, and the thing a person actually wants to know is whether taking the medicine means fewer heart attacks and strokes. The trial built to answer it is registered as NCT06008756, with roughly 14,550 participants at high cardiovascular risk. Its main measurement is the time to a first major cardiovascular event, and the registry entry gives November 2029 as the estimated date for collecting it [4].

The published record also says nothing about how this tablet compares with the injected antibodies over years, or about anyone outside the trial population. What it does establish is narrower and still a first of its kind: a peptide, closed into a ring and manufactured by enzymes, lowered a cholesterol measurement over 52 weeks when swallowed once a day, and there is now an approved label written on the assumption that people will take it that way [1][3].